Literature DB >> 33093059

Primary acquired melanosis (PAM) without atypia/WHO low-grade conjunctival melanocytic intraepithelial lesion over areas of oculodermal melanocytosis.

Bashar M Bata1,2, Sachin M Salvi3,2, Hardeep Singh Mudhar4.   

Abstract

An elderly white man with a history of left oculodermal melanocytosis presented with new onset brown pigmentation of the left bulbar and inferior tarsal conjunctiva. The bulbar conjunctival pigmentation was at the level of the conjunctival epithelium and was overlying areas of typical slate-grey scleral pigmentation characteristic of oculodermal melanocytosis. Both areas of new pigmentation were biopsied. The bulbar conjunctiva revealed primary acquired melanosis (PAM) without atypia with increased melanin production and the tarsal conjunctival biopsy showed PAM without atypia sine pigmentio overlying areas of substantia propria spindle-shaped heavily pigmented melanocytes of oculodermal melanocytosis. The case report examines the relationship between the epithelial and substantia propria melanocytes and correlates the findings with what is known about this association from the dermatopathology literature. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  ophthalmology; pathology

Mesh:

Year:  2020        PMID: 33093059      PMCID: PMC7583058          DOI: 10.1136/bcr-2020-236741

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  3 in total

1.  Congenital combined dermal and epidermal melanocytosis: a new entity?

Authors:  S Kim; J-H Park; J-A Kim; J-H Lee; J-M Yang; E-S Lee; W-S Kim
Journal:  J Eur Acad Dermatol Venereol       Date:  2007-10       Impact factor: 6.166

2.  Ocular findings in oculodermal melanocytosis.

Authors:  C Teekhasaenee; R Ritch; U Rutnin; N Leelawongs
Journal:  Arch Ophthalmol       Date:  1990-08

3.  Ocular and oculodermal melanocytosis.

Authors:  J R Gonder; J Nichol; J J Augsburger; J A Shields
Journal:  Can J Ophthalmol       Date:  1985-08       Impact factor: 1.882

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.